四川科伦博泰生物医药股份有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Kelun-Biotech Announces Interim Results for 2023: Global Strategic Partnership and Rich Pipeline Boost Significant Revenue Growth in the First Half of the Year 2023-08-28 22:56
Kelun-Biotech announces that a Phase III clinical trial of core product SKB264 (MK-2870, TROP2-ADC) in patients with unresectable locally advanced, recurrent or metastatic TNBC who have failed second-line or above prior standard of care has met its primary endpoint 2023-08-14 12:50
Selected for oral presentation! Kelun-Biotech to announce latest clinical study results of SKB264 (MK-2870, TROP2-ADC) for treatment of HR+/HER2- breast cancer at ESMO Congress 2023 2023-08-01 21:07
1 2 3